The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
https://www.linkedin.com/jobs/view/3451495788
97 applicants - seems alot.
This seems relevant
https://ippsecretariat.org/news/second-100-day-mission-implementation-report/
Also daneeka, re MERS- you remember the first SARS? I do.
That's the point. It's not about does it/doesn't it work. It's about a large enough sample size in a single trial to show statistical significance.
Or maybe they'll gain accelerated approval based on surrogate endpoints based on the recently passed laws in the states and use strive as a P4 confirmatory trial - who knows right?
Wigster - every trial the company have run from SG16 to sprinter has at least trended towards efficacy (or of course shown exceptional efficacy) and safety data is good, with a + showing on adverse events. it's a numbers game.
" The accumulated non-clinical and clinical data has strengthened our conviction that SNG001 has potential as a broad-spectrum antiviral which could be directed towards patients infected with a wide range of viruses including influenza, RSV, coronaviruses, parainfluenza viruses and others. As it stands today, there are no broad-spectrum antivirals approved for use in patients with severe viral lung infections who are at increased risk of progressing to severe disease or death, and this is in the context of more than 3 million people a year being hospitalised due to these infections in the US alone. It is then perhaps not surprising that this also means there is no precedent for a broad-spectrum antiviral clinical development programme. Designing and determining a clinical pathway for this approach is complex, as there are multiple viruses being targeted for different high-risk patient groups.
This is our absolute focus. The Synairgen team, and our partners and advisors, have been working relentlessly to identify the optimal clinical development programme to confirm the signals we have seen, and investigate SNG001 against this wide spectrum of respiratory viruses."
Believe this is a repost of the same
https://twitter.com/healthbyjames/status/1618043974811516928
Believe this is a repost of the same
https://twitter.com/healthbyjames/status/1618043974811516928
https://www.simplyhired.com/job/BMyWirEy1xHCtWv2SiR8LKWdq05zbJ7YLS4xotXpQRu1hY3X4nuGaw?isp=0&q=synairgen
Quite the find this morning by a SNG LTH :)
Full Job Description
Ashfield Engage has partnered with Synairgen, an emerging respiratory biotech company, to hire an Associate Medical Affairs Director in the Respiratory Virology therapeutic area.
Synairgen is an agile and pioneering specialist respiratory biotech company.
Synairgen’s primary focus is the clinical development of SNG001 (inhaled interferon beta) for severe lower respiratory infections, including COVID-19, as potentially the first host-targeted broad-spectrum antiviral treatment delivered directly into the lungs. Synairgen is led by a team of industry experts and world-renowned academics, dedicated to creating pandemic-ready respiratory treatments we can all believe in. Synairgen is quoted on the London Stock Exchange’s AIM (LSE: SNG).
The Associate Medical Affairs Director is responsible for managing Synairgen’s relationships with external medical stakeholders, to enable evaluation & preparation for the introduction of SNG001 into clinical practice, post Regulatory approval. Working closely with senior management, this position will have a major impact on setting Medical Affairs Strategies and is accountable for management of Medical Affairs initiatives spanning both office and field-based medical activities in support of SNG001.
This is your opportunity to lead North American medical strategies & stakeholder engagement, with the potential to extend the implementation globally.